AiCuris: AiCuris gets 30 million Euros milestone payment from MSD following US FDA approval of Prevymis in second indication
AiCuris Anti─infective Cures AG, a leading clinical─stage pharmaceutical company, announced that it has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (Merck &
Read full article »
AiCuris is a Germany-based pharmaceutical company that discovers, researches and develops antiviral and antibacterial agents for the treatment of infectious diseases.
Read more